R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.

Slides:



Advertisements
Similar presentations
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
Surveillance of Heart Diseases and Stroke Using Centers for Medicare and Medicaid (CMS) Data: A Researcher’s Perspective Judith H. Lichtman, PhD MPH Associate.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
ADVANCE - post trial ObservatioNal Study Key results “Hot Topics in Diabetes” 50 th EASD, Vienna 2014.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Randomized, double-blind, multicenter, controlled trial.
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Clinical Outcomes with Newer Antihyperglycemic Agents
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Glycemic Control: When the Lower is Not the “Better”?
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Prevalence (%) estimates of diabetes (20-79 years) 2010.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Angela Aziz Donnelly April 5, 2016
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
Clinical Outcomes with Newer Antihyperglycemic Agents
The SPRINT Research Group
Patient populations by study group figure 10
Larissa Registry on CAS and CEA:
HOPE: Heart Outcomes Prevention Evaluation study
Diabetes and Risk of CV Outcomes
SAVE Trial design: Patients with moderate to severe obstructive sleep apnea (OSA) and known CV disease were randomized in a 1:1 fashion to either CPAP.
EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.
Diabetes Journal Club March 17, 2011
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Cohort and Community Surveillance Components
Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.
Presentation transcript:

R1 강민혜 / prof. 전숙

Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related to cardiovascular events are an order of magnitude greater than that related to microvascular events. Most observational studies have shown an association between glucose control and cardiovascular disease. ACCORDADVANCEVADTUKPDS Median age: 62yrs old HbA1c ≤6.0% vs 7~7.9 Median 5.6yrs Increased mortality Median age: 65yrs old, 10yrs DM Hx. HbA1c ≤6.5% vs 7~7.9 Median 5yrs microvascular event ↓ Median age: 60.5yrs old 11.5yrs DM Hx. HbA1c difference: 1.5% Median 5.6yrs No benefit to CVD Median age: 53yrs old Newly diagnosed DM Median 10yrs

Introduction We report cardiovascular outcomes after an extended follow-up period of the VADT VADT ; a multisite, randomized, controlled trial of intensive versus standard glucose control in U.S. military veterans with type 2 diabetes, in which patients were followed for up to 7.5 years The current prespecified analysis includes approximately 5 additional years of observational follow-up of the study cohort.

Methods  Original study design 1791 military veterans with type 2 DM a multisite, randomized, controlled trial intensive or standard glucose control The interventional component of the study ended on May 29, 2008 (median follow-up, 5.6 years). → national data registry, yearly survey, chart reviews

Methods  Data sources Four national data registries - the central VA medical information files, - the Centers for Medicare and Medicaid Services (CMS) Medicare claims files - the VA death files -the National Death Index (NDI) Annual self-administered survey: major events, care center ≤65yrs, an event outside the VA system → hospital record Median 9.8years (up to 11.8yrs)

Methods  Primary and Secondary outcomes Primary outcome ; the time to the first major cardiovascular event (a composite of heart attack, stroke, new or worsening congestive heart failure, death from cardiovascular causes, or amputation for ischemic gangrene) Secondary outcome ; Cardiovascular mortality and total mortality. (-) selected cardiac procedure new pph vascular disease (2009)

Results -Characteristics of the Patients Complete cohort 92.4% Survey cohort 77.7%

Results -Characteristics of the Patients

2009’ VADT 2015’

Results - Primary Outcome and Secondary Outcomes -17%

Conclusion After nearly 10 years of follow-up, patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person- years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival.